Zacks Investment Research lowered shares of ProQR Therapeutics (NASDAQ:PRQR) from a buy rating to a hold rating in a research note issued to investors on Tuesday morning.

According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “

A number of other equities analysts also recently commented on PRQR. HC Wainwright reiterated a buy rating and issued a $40.00 price target on shares of ProQR Therapeutics in a research note on Tuesday, September 26th. Leerink Swann reiterated an outperform rating and issued a $12.00 price target (up from $10.00) on shares of ProQR Therapeutics in a research note on Tuesday, September 26th. ValuEngine downgraded ProQR Therapeutics from a hold rating to a sell rating in a research note on Tuesday, September 26th. Chardan Capital reiterated a neutral rating on shares of ProQR Therapeutics in a research note on Sunday, September 17th. Finally, JMP Securities lifted their price target on ProQR Therapeutics from $14.00 to $20.00 and gave the stock an outperform rating in a research note on Tuesday, September 26th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. ProQR Therapeutics has a consensus rating of Buy and a consensus target price of $18.94.

ProQR Therapeutics (NASDAQ PRQR) traded down $0.20 during trading hours on Tuesday, reaching $3.10. The company had a trading volume of 125,044 shares, compared to its average volume of 72,453. The firm has a market capitalization of $105.14, a P/E ratio of -1.63 and a beta of 0.62. ProQR Therapeutics has a fifty-two week low of $2.75 and a fifty-two week high of $6.90. The company has a quick ratio of 6.72, a current ratio of 6.72 and a debt-to-equity ratio of 0.20.

ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings results on Monday, November 20th. The biopharmaceutical company reported ($0.49) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.52) by $0.03. analysts expect that ProQR Therapeutics will post -1.71 earnings per share for the current fiscal year.

A number of large investors have recently bought and sold shares of the stock. Nine Chapters Capital Management LLC acquired a new position in ProQR Therapeutics in the third quarter valued at approximately $133,000. Wells Fargo & Company MN boosted its stake in ProQR Therapeutics by 212.6% in the third quarter. Wells Fargo & Company MN now owns 43,226 shares of the biopharmaceutical company’s stock valued at $210,000 after acquiring an additional 29,400 shares during the period. Redmile Group LLC boosted its stake in ProQR Therapeutics by 2.8% in the second quarter. Redmile Group LLC now owns 1,596,275 shares of the biopharmaceutical company’s stock valued at $8,301,000 after acquiring an additional 43,050 shares during the period. Artal Group S.A. boosted its stake in ProQR Therapeutics by 25.0% in the second quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock valued at $2,600,000 after acquiring an additional 100,000 shares during the period. Finally, Sphera Funds Management LTD. boosted its stake in ProQR Therapeutics by 60.6% in the third quarter. Sphera Funds Management LTD. now owns 530,000 shares of the biopharmaceutical company’s stock valued at $2,571,000 after acquiring an additional 200,000 shares during the period. Institutional investors and hedge funds own 31.63% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “ProQR Therapeutics (PRQR) Cut to Hold at Zacks Investment Research” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/proqr-therapeutics-prqr-cut-to-hold-at-zacks-investment-research/1805830.html.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein.

Get a free copy of the Zacks research report on ProQR Therapeutics (PRQR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.